GRPH - Graphite Bio, Inc.
Graphite Bio, Inc.
201 Haskins Way
Suite 210
South San Francisco, CA 94080
United States
(650) 484-0886
https://graphitebio.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 120
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Joshua Lehrer-Graiwer FACC, M.D. | Pres, CEO & Director | 785.25k | N/A | 1975 |
| Dr. Matthew Porteus M.D., Ph.D. | Academic Founder & Director | 110k | N/A | 1966 |
| Ms. Alethia Rene Young | Chief Financial Officer | 774.12k | N/A | 1979 |
| Dr. Maria Grazia Roncarolo M.D., Ph.D. | Academic Founder & Chair of Scientific Advisory Board | N/A | N/A | 1954 |
| Dr. Daniel Dever Ph.D. | Co-Founder & Head of Discovery Research | N/A | N/A | N/A |
| Dr. Christine Garrett P.M.P., Ph.D. | Chief of Staff & Sr. VP of Operations | N/A | N/A | 1971 |
| Mr. Jerry Cacia | Chief Technical Officer | N/A | N/A | 1967 |
| Stephanie Yao | VP of Communications & Investor Relations | N/A | N/A | N/A |
| Ms. Julia Tran | Chief People Officer | N/A | N/A | 1977 |
| Mr. Darren Hart B.S.N., J.D. | Sr. VP of Devel. | N/A | N/A | N/A |
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH102 for the treatment of beta-thalassemia; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Corporate governance
Graphite Bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
